{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:00:26Z","timestamp":1775743226857,"version":"3.50.1"},"reference-count":4,"publisher":"Harborside Press, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.6004\/jnccn.2026.0019","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:50:17Z","timestamp":1775739017000},"source":"Crossref","is-referenced-by-count":0,"title":["Curing Prostate Cancer?"],"prefix":"10.6004","volume":"24","author":[{"given":"Daniel M.","family":"Geynisman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"J Clin Oncol","first-page":"Abstract 17","article-title":"Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer (mCRPC)","volume":"44","author":"de Bono JS","year":"2026","unstructured":"de Bono JS, Fenor de la Maza MD, Boni V,  Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2026;44(Suppl):Abstract 17."},{"key":"B2","series-title":"J Clin Oncol","first-page":"JCO2502834","article-title":"Trial design and objectives for patients with prostate cancer: recommendations from the Prostate Cancer Working Group 4","author":"Armstrong AJ","year":"2026","unstructured":"Armstrong AJ, Morris MJ, Abida W,  Trial design and objectives for patients with prostate cancer: recommendations from the Prostate Cancer Working Group 4. J Clin Oncol 2026;JCO2502834."},{"key":"B1","series-title":"J Clin Oncol","first-page":"Abstract 17","article-title":"Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer (mCRPC)","volume":"44","author":"de Bono JS","year":"2026","unstructured":"de Bono JS, Fenor de la Maza MD, Boni V,  Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2026;44(Suppl):Abstract 17."},{"key":"B2","series-title":"J Clin Oncol","first-page":"JCO2502834","article-title":"Trial design and objectives for patients with prostate cancer: recommendations from the Prostate Cancer Working Group 4","author":"Armstrong AJ","year":"2026","unstructured":"Armstrong AJ, Morris MJ, Abida W,  Trial design and objectives for patients with prostate cancer: recommendations from the Prostate Cancer Working Group 4. J Clin Oncol 2026;JCO2502834."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/4\/article-e260019.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/4\/article-e260019.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/4\/article-e260019.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:08:10Z","timestamp":1775740090000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/4\/article-e260019.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":4,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.0019","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}